European drug regulators approved the higher-dose version of Wegovy in February. Called Wegovy HD, the higher-dose drug helped participants in a study lose about 19% of their body weight, or almost 47 ...

By Christy Santhosh March 19 (Reuters) - Eli Lilly's next-generation obesity drug showed a significant reduction in blood sugar levels and weight in a late-stage trial, the company said on Thursday, ...

Rendering a drug effective or ineffective in a flash at the appropriate location—this is the focus of research in photopharmacology. The goal is to develop drugs that can be switched on and off with ...

Patients with obesity sometimes have leptin resistance, and the "full" feeling does not get through to the brain. The new research isolates enzymes that act like valves, preventing the flow of leptin.

In India, China and several other nations, Novo Nordisk is on the verge of losing patent protection for its blockbuster ...

Novo Nordisk's reports to the FDA spiked shortly after an inspection found the Ozempic producer ignored reports of deaths and potential side effects.

For centuries, humans have sought cures for all types of illnesses, from simple pain relief to drugs that tackle some of the most devastating diseases, like cancer. Researchers in pharmacology have ...

Have you noticed the side effects listed for one of those new drugs being advertised on TV? It may seem as if one of those marvelous medicines might be a good solution for your problem, but the long ...

New research suggests that statins do not cause the majority of side effects listed on their labels, including memory problems, depression, and sleep issues. The corresponding study was published in ...

It’s worth the weight — loss, that is. Despite their blockbuster popularity, GLP-1 medications come with a handful of side effects, mainly along the lines of gastrointestinal issues like nausea and ...

Feb 3 (Reuters) - Pfizer on Tuesday released trial data on a high-profile ‌obesity drug from its recent $10 billion Metsera purchase that raises ‌questions about its tolerability for patients, and ...